Want to see SER full AI Analyst Report?
Top Page
Serina Therapeutics
(SER)
Select Model
Select Model
Rating:48Neutral
Price Target:
$3.00
▲(44.93% Upside)
Action:Reiterated
Date:08/17/26
The score is primarily held down by weak financial performance (no revenue, sizable losses, and heavy free-cash-flow burn), which increases future financing and dilution risk. Technicals are supportive with strong trend/momentum, but overbought readings temper that strength. Corporate actions add some strategic and governance positives, while valuation inputs are constrained by negative earnings and no dividend data.
Positive Factors
Low financial leverage
Minimal debt gives Serina greater financial flexibility than a highly leveraged biotech and limits near-term interest burden. This supports the company’s ability to direct available capital toward clinical development, although it does not eliminate its need for future funding.
Negative Factors
No current revenue and deep losses
Serina has not established recurring commercial revenue, while substantial operating and net losses show that the business remains dependent on development investment. The collapse from $3.15M of 2023 revenue to near-zero in 2024 also indicates limited operating scale.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage
Minimal debt gives Serina greater financial flexibility than a highly leveraged biotech and limits near-term interest burden. This supports the company’s ability to direct available capital toward clinical development, although it does not eliminate its need for future funding.
Read all positive factors
Serina Therapeutics (SER) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$72.90M
Dividend YieldN/A
Average Volume (3M)24.47K
Price to Earnings (P/E)―
Beta (1Y)0.19
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.88
Shares Outstanding25,400,473
10 Day Avg. Volume14,098
30 Day Avg. Volume24,472
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-526.02
Price to Sales (P/S)0.00
P/FCF Ratio-1.08
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.50Price Target Upside358.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.73
Revenue Forecast (FY)N/A
Serina Therapeutics Business Overview & Revenue Model
Company Description
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The compa...
How the Company Makes Money
null...
Serina Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
54
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 56.00K | 3.15M | 500.00K | 3.46M |
| Gross Profit | -7.07M | 0.00 | -138.00K | 3.06M | 500.00K | -333.84K |
| EBITDA | -22.15M | -18.91M | -10.49M | 5.92M | -2.60M | -1.23M |
| Net Income | -21.18M | -19.18M | -11.14M | 5.27M | -2.68M | -1.26M |
Balance Sheet | ||||||
| Total Assets | 25.81M | 6.95M | 6.72M | 8.97M | 3.24M | 3.15M |
| Cash, Cash Equivalents and Short-Term Investments | 23.02M | 3.06M | 3.67M | 7.62M | 645.00K | 584.00K |
| Total Debt | 3.21M | 196.00K | 268.00K | 3.44M | 18.12M | 13.20M |
| Total Liabilities | 7.08M | 6.99M | 6.22M | 41.26M | 20.56M | 15.03M |
| Stockholders Equity | 18.73M | -37.00K | 641.00K | 4.11M | -17.21M | -11.83M |
Cash Flow | ||||||
| Free Cash Flow | -21.17M | -17.95M | -17.16M | -2.98M | -2.09M | -2.36M |
| Operating Cash Flow | -21.14M | -17.95M | -17.14M | -2.48M | -2.08M | -2.25M |
| Investing Cash Flow | -66.00K | -59.00K | -22.00K | -504.00K | 980.94K | 823.32K |
| Financing Cash Flow | 38.18M | 17.41M | 13.21M | 10.07M | 1.31M | 1.08M |
Serina Therapeutics Technical Analysis
Positive
2.07
Price Trends
2.20
Positive
2.03
Positive
2.35
Positive
Market Momentum
0.18
Negative
56.23
Neutral
54.28
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SER, the sentiment is Positive. The current price of 2.07 is below the 20-day moving average (MA) of 2.48, below the 50-day MA of 2.20, and below the 200-day MA of 2.35, indicating a bullish trend. The MACD of 0.18 indicates Negative momentum. The RSI at 56.23 is Neutral, neither overbought nor oversold. The STOCH value of 54.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SER.
Serina Therapeutics Risk Analysis
Serina Therapeutics disclosed 74 risk factors in its most recent earnings report. Serina Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Serina Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $72.90M | -1.40 | -222.42% | ― | ― | ― | |
48 Neutral | $157.56M | -0.50 | 222.01% | ― | ― | ― | |
48 Neutral | $23.16M | -0.21 | 411.46% | ― | -51.03% | -35.20% | |
46 Neutral | $25.40M | -0.59 | -63.87% | ― | -100.00% | 41.21% | |
42 Neutral | $79.34M | -0.21 | -329.08% | ― | ― | -19.07% |
* Healthcare Sector Average
SER
Serina Therapeutics
2.63
-2.86
-52.09%
OTLK
Outlook Therapeutics
0.61
-2.09
-77.44%
SKYE
Skye Bioscience
2.17
-26.43
-92.41%
CELU
Celularity
0.77
-3.16
-80.31%
BRNS
Barinthus Biotherapeutics
0.60
-0.59
-49.33%
JUNS
Jupiter Neurosciences, Inc.
5.66
-105.34
-94.90%
Serina Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Serina Therapeutics Amends CEO Employment and Compensation Terms
Neutral
Jul 23, 2026
On July 19, 2026, Serina Therapeutics, Inc. and its Alabama subsidiary entered into an Amended and Restated Employment Agreement with CEO Steve Ledger that fully replaces his September 9, 2024 contract. The new agreement sets his annual base salar...
Business Operations and StrategyExecutive/Board Changes
Serina Therapeutics Adds Industry Veteran to Board
Positive
Jul 22, 2026
On July 22, 2026, Serina Therapeutics, Inc. appointed Farrell Simon, Pharm. D., to its Board of Directors and to the Audit and Compensation Committees, strengthening governance with a seasoned commercial and business development executive. Simon, ...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and FinancingShareholder Meetings
Serina Therapeutics Shareholders Approve Expanded Equity and Governance
Positive
Jun 24, 2026
On June 17, 2026, Serina Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, at which shareholders approved an amendment to increase the company’s authorized common stock from 40 million to 125 million shares and elected three d...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.